

Percent Susceptible, Gram-negative bacilli 1/01/07 - 12/31/07

	Body site	Total isolates	AMK	A/S	AZM	CFZ	FEP	CAZ	CTR	GEN	IMI	PIP/TAZ	TIG	T/S	LEV**
Enterobacter species	Urine	59	100	--	73	2	100	73	74	93	100	80	--	92	90
	Other	113	100	--	83	3	100	84	86	94	100	88	89	96	95
Escherichia coli	Urine	947	100	60	99	92	99	98	98	88	99	99	100	75	76
	Other	258	100	54	95	90	97	94	94	86	100	97	100	70	63
Klebsiella pneumoniae	Urine	228	100	85	94	93	94	93	94	97	100	97	93	88	94
	Other	109	100	84	95	92	95	94	95	97	100	97	94	95	96
Proteus species	Urine	84	100	80	99	92	99	99	98	86	--	100	24	83	71
	Other	65	100	85	100	91	100	100	100	92	--	100	26	80	74
Pseudomonas aeruginosa	CF sputum*	250	33	--	41	--	46	51	--	33	48	52	--	--	32
	Urine	111	82	--	--	--	76	78	--	69	84	83	0	--	66
	Other	185	90	--	--	--	85	78	--	82	85	88	1	--	81
Serratia marcescens	ALL	57	100	--	100	0	100	98	98	100	98	100	90	96	96
Morganella morganii	ALL	17	100	0	94	0	100	79	100	76	--	100	64	76	88
Acinetobacter species	ALL	99	96	--	--	--	56	48	19	61	78	--	55	58	60
Citrobacter freundii	ALL	33	100	--	82	0	94	82	79	82	100	--	81	48	64
Citrobacter koseri (C. diversus)	ALL	32	100	--	100	94	100	97	100	100	100	--	96	100	91
										* sputa from patients with Cystic Fibrosis					
	Body site	Total isolates	CAZ	CLR	T/S	LEV	MIN	MER	T/CL	** Susceptibility rates for Ciprofloxacin are similar to those of Levofloxacin					
Burkholderia cepacia	ALL	4	100	--	75	75	--	100	0						
Stenotrophomonas maltophilia	ALL	92	32	--	78	64	96	--	33						

-- = Not reported

Percent Susceptible, Gram-positive cocci 1/01/06 - 12/31/06

	Body Site	Total Isolates	AMP	CLR	CLN	ERY	GEN SNG <sup>■</sup>	OXA	LEV	TET	T/S	VAN	PCN	LZD	D/P
Staphylococcus aureus	ALL	1160	--	--	80	27	--	39	--	94	99	100	8	100 <sup>c</sup>	--
Coag-neg-staph species	ALL	581	--	--	61	28	--	22	--	76	--	99	2	100	--
Enterococcus faecium	ALL	233	4	88 <sup>b***</sup>	--	--	92	--	--	--	--	23	4	99 <sup>b***</sup>	100 <sup>b***</sup>
Enterococcus faecalis	ALL	262	98	--	--	--	67	--	--	--	--	98	98	--	--
Streptococcus pneumoniae	ALL	41	--	90	78	68	--	--	100	--	--	100	61 <sup>‡</sup>	--	--

-- = Not Reported

Unmarked= ≥ 76% of isolates tested  
a= 51-75% of isolates tested  
b= 25-50% of isolates tested  
c= ≤ 24% of isolates tested

Colors: 2006 Yellow  
2007 Blue  
2008 Pink  
2009 Green

\*\*\* Only reported on Vancomycin Resistant Enterococci

‡17% of S. pneumoniae isolates demonstrate intermediate susceptibility and 22% demonstrate resistance to Penicillin

■ Gentamicin Synergy

### Antibiotic Regimen Cost Analysis

	Drug	Dose	Frequency	Cost/Day
AMK	Amikacin	500mg	Q8H	\$24.39
AMP	Ampicillin	2 gm	Q6H	\$80.40
A/S	Ampicillin/Sulbactam	3 gm	Q6H	\$71.76
AZM	Aztreonam	1 gm	Q8H	\$124.77
CFZ	Cefazolin	1 gm	Q8H	\$21.00
FEP	Cefepime	1 gm	Q12H	\$47.00
FEP	Cefepime	2 gm	Q12H	\$91.50
CTX	Cefotaxime	1 gm	Q8H	\$38.28
CTX	Cefotaxime	2 gm	Q8H	\$64.29
--	Cefoxitin	2 gm	Q6h	\$108.76
CAZ	Ceftazidime	2 gm	Q8H	\$63.75
CTR	Ceftriaxone	1 gm	Q24H	\$10.75
CLR	Chloramphenicol	900 mg	Q6H	\$119.76
CIP	Ciprofloxacin	--	--	
CLN	Clindamycin	900 mg	Q8H	\$49.74
D/P	Dalfo/Quinu	500 mg	Q8H	\$661.20
D/P	Dalfo/Quinu	500 mg	Q12H	\$341.32
ERY	Erythromycin	500 mg	Q6H	\$42.36
GEN	Gentamicin	80 mg	Q8H	\$29.73
IMI	Imipenem/Cilastatin	500 mg	Q6H	\$169.64
LEV	Levofloxacin	500 mg	QD	\$45.65
LZD	Linezolid	600 mg	Q12H	\$210.12
MER	Meropenem	1 gm	Q8H	\$230.34
--	Metronidazole	500 mg	Q6H	\$61.36
MIN	Minocycline	--	--	
--	Nafcillin	2 gm	Q4H	\$132.06
OXA	Oxacillin	--	--	
PCN	Penicillin	2 MU	Q4H	\$65.94
PIP/TAZ	Piperacillin/Taxob	3/0.3	Q6H	\$101.32
PIP/TAZ	Piperacillin/Taxob	4/0.5	Q6H	\$128.36
TET	Tetracycline	--	--	
T/CL	Ticaracillin/clavulanic	3.1 gm	Q4H	\$101.94
TOB	Tobramycin	80 mg	Q8H	\$21.84
TIG	Tigecycline	50 mg	Q12H	\$126.40
T/S	Trimethoprim/Sulfam	350/1750 mg	Q6H	\$1.60
VAN	Vancomycin	1 gm	Q12H	\$72.00

These costs are acquisition costs for the UAMS Medical Center based on bid contract prices and are not reflective of drug prices in other institutions. The costs of these therapies may vary due to wholesaler availability. Some costs are based on vials only, whereas, others include cost of drug, cost of materials to prepare the drug for administration via Advantage System® or Frozen Minibags (Department of Pharmacy stock).

Division of Health, Arkansas Department of Health and Human Services' regulations require reporting of certain communicable diseases. Please report any of the following *suspected OR confirmed IMMEDIATELY* to (501) 661-2893 (Monday - Friday, 8 a.m. - 4:30 p.m.) or 1 (800) 554-5738 (after hours and weekends):

Anthrax	Pertussis	Tularemia
Botulism	Plague	Typhus
Hepatitis A	Q Fever	Viral Hemorrhagic Fevers
Meningococcal	SARS	Emerging Threat Agents
Infx.	Smallpox	

Please report any of the following to the hospital epidemiologist at either 686-7141 or 686-8568:

AIDS	Leprosy (Hansen's disease)
Blastomycosis	Listeriosis
CD4+ T-Lymphocyte Count	Lyme Disease
Campylobacteriosis	Malaria
Chancroid	Measles (Rubeola)
Chlamydial infections	Meningitis
Cholera	Mumps
Congenital Rubella Syndrome	Poliomyelitis
Congenital Syphilis	Psittacosis
Creutzfeldt-Jakob Disease	Rabies, animal
Cryptosporidiosis	Rabies, human
Diphtheria	Rheumatic fever
Ehrlichiosis	Rocky Mountain Spotted Fever
Encephalitis, all types	Rubella
Enterotoxigenic E. coli	Salmonellosis (including Typhoid)
Food poisoning, all types	Shigellosis
Giardiasis	Streptococcal Disease, invasive, group
Gonorrhea	Streptococcus pneumoniae, invasive
Haemophilus influenzae, invasive disease	(Indicate if antibiotic resistant)
Hantavirus Pulmonary Syndrome	Syphilis
HbsAg-positive pregnant female	Tetanus
Hepatitis (type A, B, C, or unspecified)	Toxic Shock Syndrome
Histoplasmosis	Toxoplasmosis
HIV (Human Immunodeficiency Virus)	Tuberculosis
Influenza (viral type, if known)	Vancomycin-resistant enterococci
Influenza deaths in persons < 18 years old	Varicella (chickenpox)
Kawasaki Disease	West Nile Virus
Legionellosis	Yellow Fever

# Antibiogram

January 1, 2007 to December 31, 2007

**UAMS**  
**MEDICAL**  
**CENTER**

UNIVERSITY OF ARKANSAS  
FOR MEDICAL SCIENCES